vs
乐至宝（LZB）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是乐至宝的1.4倍（$772.1M vs $541.6M），Revvity净利率更高（12.7% vs 4.0%，领先8.7%），Revvity同比增速更快（5.9% vs 3.8%），Revvity自由现金流更多（$161.8M vs $71.6M），过去两年Revvity的营收复合增速更高（9.0% vs -1.1%）
La-Z-Boy是总部位于美国密歇根州门罗的家具制造企业，主打居家家具产品，涵盖软垫 recliner、沙发、固定座椅、升降椅、沙发床等品类，全球员工规模超过11000人，是休闲家居领域的知名品牌。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
LZB vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.4倍
$541.6M
营收增速更快
RVTY
高出2.1%
3.8%
净利率更高
RVTY
高出8.7%
4.0%
自由现金流更多
RVTY
多$90.2M
$71.6M
两年增速更快
RVTY
近两年复合增速
-1.1%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $541.6M | $772.1M |
| 净利润 | $21.6M | $98.4M |
| 毛利率 | 43.1% | — |
| 营业利润率 | 5.5% | 14.5% |
| 净利率 | 4.0% | 12.7% |
| 营收同比 | 3.8% | 5.9% |
| 净利润同比 | -23.8% | 3.9% |
| 每股收益（稀释后） | $0.52 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LZBRVTY
| Q1 26 | $541.6M | — | ||
| Q4 25 | $522.5M | $772.1M | ||
| Q3 25 | $492.2M | $698.9M | ||
| Q2 25 | $570.9M | $720.3M | ||
| Q1 25 | $521.8M | $664.8M | ||
| Q4 24 | $521.0M | $729.4M | ||
| Q3 24 | $495.5M | $684.0M | ||
| Q2 24 | $553.5M | $691.7M |
净利润LZBRVTY
| Q1 26 | $21.6M | — | ||
| Q4 25 | $28.9M | $98.4M | ||
| Q3 25 | $18.2M | $46.7M | ||
| Q2 25 | $14.9M | $53.9M | ||
| Q1 25 | $28.4M | $42.2M | ||
| Q4 24 | $30.0M | $94.6M | ||
| Q3 24 | $26.2M | $94.4M | ||
| Q2 24 | $39.3M | $55.4M |
毛利率LZBRVTY
| Q1 26 | 43.1% | — | ||
| Q4 25 | 44.2% | — | ||
| Q3 25 | 42.5% | 53.6% | ||
| Q2 25 | 44.0% | 54.5% | ||
| Q1 25 | 44.3% | 56.5% | ||
| Q4 24 | 44.3% | — | ||
| Q3 24 | 43.1% | 56.3% | ||
| Q2 24 | 43.4% | 55.7% |
营业利润率LZBRVTY
| Q1 26 | 5.5% | — | ||
| Q4 25 | 6.9% | 14.5% | ||
| Q3 25 | 4.5% | 11.7% | ||
| Q2 25 | 5.2% | 12.6% | ||
| Q1 25 | 6.7% | 10.9% | ||
| Q4 24 | 7.4% | 16.3% | ||
| Q3 24 | 6.5% | 14.3% | ||
| Q2 24 | 9.1% | 12.4% |
净利率LZBRVTY
| Q1 26 | 4.0% | — | ||
| Q4 25 | 5.5% | 12.7% | ||
| Q3 25 | 3.7% | 6.7% | ||
| Q2 25 | 2.6% | 7.5% | ||
| Q1 25 | 5.4% | 6.4% | ||
| Q4 24 | 5.8% | 13.0% | ||
| Q3 24 | 5.3% | 13.8% | ||
| Q2 24 | 7.1% | 8.0% |
每股收益（稀释后）LZBRVTY
| Q1 26 | $0.52 | — | ||
| Q4 25 | $0.70 | $0.86 | ||
| Q3 25 | $0.44 | $0.40 | ||
| Q2 25 | $0.35 | $0.46 | ||
| Q1 25 | $0.68 | $0.35 | ||
| Q4 24 | $0.71 | $0.77 | ||
| Q3 24 | $0.61 | $0.77 | ||
| Q2 24 | $0.91 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $306.1M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.0B | $7.3B |
| 总资产 | $2.1B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LZBRVTY
| Q1 26 | $306.1M | — | ||
| Q4 25 | $338.5M | $919.9M | ||
| Q3 25 | $318.5M | $931.4M | ||
| Q2 25 | $328.4M | $991.8M | ||
| Q1 25 | $314.6M | $1.1B | ||
| Q4 24 | $303.1M | $1.2B | ||
| Q3 24 | $342.3M | $1.2B | ||
| Q2 24 | $341.1M | $2.0B |
股东权益LZBRVTY
| Q1 26 | $1.0B | — | ||
| Q4 25 | $1.0B | $7.3B | ||
| Q3 25 | $1.0B | $7.4B | ||
| Q2 25 | $1.0B | $7.6B | ||
| Q1 25 | $1.0B | $7.6B | ||
| Q4 24 | $1.0B | $7.7B | ||
| Q3 24 | $999.2M | $7.9B | ||
| Q2 24 | $1.0B | $7.9B |
总资产LZBRVTY
| Q1 26 | $2.1B | — | ||
| Q4 25 | $2.0B | $12.2B | ||
| Q3 25 | $1.9B | $12.1B | ||
| Q2 25 | $1.9B | $12.4B | ||
| Q1 25 | $2.0B | $12.4B | ||
| Q4 24 | $1.9B | $12.4B | ||
| Q3 24 | $1.9B | $12.8B | ||
| Q2 24 | $1.9B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $89.4M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $71.6M | $161.8M |
| 自由现金流率自由现金流/营收 | 13.2% | 21.0% |
| 资本支出强度资本支出/营收 | 3.3% | 2.6% |
| 现金转化率经营现金流/净利润 | 4.13× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $158.2M | $509.4M |
8季度趋势，按日历期对齐
经营现金流LZBRVTY
| Q1 26 | $89.4M | — | ||
| Q4 25 | $50.0M | $182.0M | ||
| Q3 25 | $36.3M | $138.5M | ||
| Q2 25 | $62.0M | $134.3M | ||
| Q1 25 | $57.0M | $128.2M | ||
| Q4 24 | $15.9M | $174.2M | ||
| Q3 24 | $52.3M | $147.9M | ||
| Q2 24 | $52.8M | $158.6M |
自由现金流LZBRVTY
| Q1 26 | $71.6M | — | ||
| Q4 25 | $29.6M | $161.8M | ||
| Q3 25 | $17.8M | $120.0M | ||
| Q2 25 | $39.3M | $115.5M | ||
| Q1 25 | $38.2M | $112.2M | ||
| Q4 24 | $-1.2M | $149.8M | ||
| Q3 24 | $36.7M | $125.6M | ||
| Q2 24 | $37.3M | $136.6M |
自由现金流率LZBRVTY
| Q1 26 | 13.2% | — | ||
| Q4 25 | 5.7% | 21.0% | ||
| Q3 25 | 3.6% | 17.2% | ||
| Q2 25 | 6.9% | 16.0% | ||
| Q1 25 | 7.3% | 16.9% | ||
| Q4 24 | -0.2% | 20.5% | ||
| Q3 24 | 7.4% | 18.4% | ||
| Q2 24 | 6.7% | 19.7% |
资本支出强度LZBRVTY
| Q1 26 | 3.3% | — | ||
| Q4 25 | 3.9% | 2.6% | ||
| Q3 25 | 3.8% | 2.6% | ||
| Q2 25 | 4.0% | 2.6% | ||
| Q1 25 | 3.6% | 2.4% | ||
| Q4 24 | 3.3% | 3.4% | ||
| Q3 24 | 3.2% | 3.3% | ||
| Q2 24 | 2.8% | 3.2% |
现金转化率LZBRVTY
| Q1 26 | 4.13× | — | ||
| Q4 25 | 1.73× | 1.85× | ||
| Q3 25 | 1.99× | 2.97× | ||
| Q2 25 | 4.15× | 2.49× | ||
| Q1 25 | 2.01× | 3.03× | ||
| Q4 24 | 0.53× | 1.84× | ||
| Q3 24 | 2.00× | 1.57× | ||
| Q2 24 | 1.34× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LZB
| Stationary Upholstery Furniture | $286.2M | 53% |
| Retail Segment | $251.9M | 47% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
